Log in to search using one of your social media accounts:


Roche's star MS medicine Ocrevus wins EU approval

ZURICH (Reuters) - The European Union approved Roche's multiple sclerosis medicine Ocrevus, one the Swiss company's key new drugs that likely neared $1 billion in revenue in its first nine months on the U.S. market.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

Authors: Honore T, Le Breton F, Turmel N, Bignani B, Chesnel C, Charlanes A, Amarenco G Abstract PURPOSE: To evaluate safety and efficacy of botulinum toxin A injections in the urethral striated sphincter in patients with difficulties to perform self-intermittent catherization. METHODS: In this prospective study, 12 patients suffering from upper motor neuron diseases (8 multiple sclerosis, 2 myelitis, 1 brain injury, 1 multi system atrophy) and with difficulties to perform self-intermittent catherization, defined by a ICDQ score>1 (Intermittent Catheterization Difficulty Questionnair...
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
AbstractIntroductionRituximab is considered as a potential therapeutic option in relapsing-remitting (RRMS) and progressive forms (PMS) of multiple sclerosis (MS).ObjectiveTo investigate the effectiveness and safety of rituximab in MS.Patients and methodsObservational study of effectiveness (clinical and radiological) and safety of rituximab in RRMS and PMS.ResultsA total of 90 rituximab-treated patients were collected: 31 RRMS and 59 PMS All patients had an active disease despite standard treatment. The annualized relapse rate (ARR) the year before rituximab was 0.86, 53.3% of patients had gadolinium enhanced lesion, and ...
Source: Journal of Neurology - Category: Neurology Source Type: research
This article was corrected online.
Source: JAMA Neurology - Category: Neurology Source Type: research
AbstractAnti-JC virus (JCV) antibody index is the predictive factor of progressive multifocal leukoencephalopathy (PML) for multiple sclerosis (MS) patients treating with natalizumab. The aim of this study is to evaluate the prevalence of anti-JCV antibody positivity and index among Iranian patients who are the candidate for natalizumab and its correlation with their demographic data and previous therapies. A cross-sectional design was assessed for receiving anti-JCV antibody test results between January 2014 and December 2016. Demographic data and disease characteristics were also obtained. Statistical analysis and logist...
Source: Journal of NeuroVirology - Category: Neurology Source Type: research
There is a paucity of knowledge concerning erythrocytes in the aetiology of Multiple Sclerosis (MS) despite their potential to contribute to disease through impaired antioxidant capacity and altered haemorheol...
Source: BMC Medical Genomics - Category: Genetics & Stem Cells Authors: Tags: Research article Source Type: research
Numerous studies have shown that diet influences the development of autoimmune diseases. However, the influence of diet on axonal damage occurring in EAE (experimental autoimmune encephalomyelitis) has not been examined. In the current study we compared changes in axonal damage and myelin thickness in spinal cords of sham- and MOG (myelin oligodendrocyte glycoprotein) peptide-immunized mice kept on a standard mouse chow (Teklad 7012) versus AIN-93  M chow which was developed for improved animal health.
Source: Journal of Neuroimmunology - Category: Allergy & Immunology Authors: Source Type: research
CONCLUSION: Dutch incidence and cost estimates based on claims were consistent with previous estimates. Prevalence estimates were somewhat higher. Drug and hospital costs were highest shortly after the diagnosis. Healthcare consumption related to comorbidities was in-line with the previously reported comorbidity estimates. PMID: 29775086 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
This article reviews the salient features about the mode of action, efficacy, safety and tolerability profile of approved oral DMTs in RRMS and reviews their place in clinical algorithms in the Middle East and North Africa (MENA) region. We conducted a systematic review using a comprehensive search of MEDLINE, PubMed, Cochrane Database of Systematic Reviews (period January 1, 1995 thru January 31, 2018). Additional searches of American Academy of Neurology and European Committee for Treatment and Research in Multiple Sclerosis abstracts from 2012 thru 2017 were performed, in addition to searches of the Food and Drug Admini...
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Conclusions: In this review we will provide animal and human research data on the current clinical neurological uses for CBD individually and in combination with Δ9-THC. We will emphasize the neuroprotective, antiinflammatory, and immunomodulatory benefits of phytocannabinoids and their applications in various clinical syndromes. PMID: 29770251 [PubMed]
Source: Surgical Neurology International - Category: Neurosurgery Tags: Surg Neurol Int Source Type: research
Authors: Baird JF, Sandroff BM, Motl RW Abstract INTRODUCTION: Mobility disability is one of the most widespread and impactful consequences of multiple sclerosis (MS). Disease modifying drugs (DMDs) may delay the progression of disability over time; however, there is minimal evidence supporting the efficacy of DMDs for reversing mobility disability or restoring ambulatory function in persons with MS. Areas covered: This review outlines symptomatic pharmacologic and non-pharmacologic therapeutic approaches that target mobility disability with the goal of restoring and improving walking function. First, the efficacy of ...
Source: Expert Review of Neurotherapeutics - Category: Neurology Tags: Expert Rev Neurother Source Type: research
More News: Health | Multiple Sclerosis | Switzerland Health